Primecap Management CO Biomarin Pharmaceutical Inc Transaction History

Primecap Management CO

$132 Billion
Q1 2024

A detailed history of Primecap Management CO transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Primecap Management CO holds 18,713,895 shares of BMRN stock, worth $1.54 Billion. This represents 1.24% of its overall portfolio holdings.

Number of Shares

18,713,895

Previous 18,414,374 1.63%

Holding current value

$1.54 Billion

Previous $1.78 Billion 7.94%

% of portfolio

1.24%

Previous 1.42%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$83.81 - $99.0 $25.1 Million - $29.7 Million	299,521 Added 1.63%	18,713,895 $1.63 Billion
Q4 2023 Feb 09, 2024	BUY	$76.22 - $98.51 $597,183 - $771,825	7,835 Added 0.04%	18,414,374 $1.78 Billion
Q3 2023 Nov 13, 2023	BUY	$85.07 - $94.48 $1.95 Million - $2.17 Million	22,920 Added 0.12%	18,406,539 $1.63 Billion
Q2 2023 Aug 11, 2023	BUY	$86.68 - $100.3 $12.2 Million - $14.1 Million	140,190 Added 0.77%	18,383,619 $1.59 Billion
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $58.1 Million - $77.7 Million	662,570 Added 3.77%	18,243,429 $1.77 Billion

Q4 2022 Feb 13, 2023	SELL	$80.93 - $108.63 $3.61 Million - $4.85 Million	-44,646 Reduced 0.25%	17,580,859 $1.82 Billion
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $4.35 Million - $5.14 Million	-52,980 Reduced 0.3%	17,625,505 $1.49 Billion
Q2 2022 Aug 11, 2022	SELL	$71.48 - $86.85 $7.22 Million - $8.77 Million	-100,985 Reduced 0.57%	17,678,485 $1.47 Billion
Q1 2022 May 11, 2022	SELL	$74.28 - $92.69 $1.88 Million - $2.35 Million	-25,310 Reduced 0.14%	17,779,470 $1.37 Billion
Q4 2021 Feb 11, 2022	SELL	$71.72 - $91.47 $9.51 Million - $12.1 Million	-132,550 Reduced 0.74%	17,804,780 $1.57 Billion
Q3 2021 Nov 12, 2021	SELL	$74.77 - $85.47 $1.18 Million - $1.34 Million	-15,736 Reduced 0.09%	17,937,330 $1.39 Billion
Q2 2021 Aug 10, 2021	SELL	$75.51 - $84.79 $15.5 Million - $17.4 Million	-204,728 Reduced 1.13%	17,953,066 $1.5 Billion
Q1 2021 May 14, 2021	BUY	$74.73 - $90.69 $734,820 - $891,754	9,833 Added 0.05%	18,157,794 $1.37 Billion
Q4 2020 Feb 08, 2021	SELL	$72.61 - $90.2 $3.16 Million - $3.93 Million	-43,580 Reduced 0.24%	18,147,961 $1.59 Billion
Q3 2020 Nov 13, 2020	BUY	$71.87 - $131.03 $22.1 Million - $40.3 Million	307,570 Added 1.72%	18,191,541 $1.38 Billion
Q2 2020 Aug 13, 2020	BUY	$79.55 - $124.22 $5.9 Million - $9.22 Million	74,204 Added 0.42%	17,883,971 $2.21 Billion
Q1 2020 May 14, 2020	BUY	$71.37 - $96.85 $106 Million - $143 Million	1,480,447 Added 9.07%	17,809,767 $1.5 Billion
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $75 Million - $101 Million	1,167,246 Added 7.7%	16,329,320 $1.38 Billion
Q3 2019 Nov 13, 2019	BUY	$67.4 - $85.11 $59.2 Million - $74.8 Million	878,321 Added 6.15%	15,162,074 $1.02 Billion
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $7.46 Million - $8.72 Million	92,880 Added 0.65%	14,283,753 $1.22 Billion
Q1 2019 May 14, 2019	BUY	$84.2 - $98.62 $479,940 - $562,134	5,700 Added 0.04%	14,190,873 $1.26 Billion
Q4 2018 Feb 12, 2019	SELL	$80.14 - $106.07 $1.87 Million - $2.47 Million	-23,312 Reduced 0.16%	14,185,173 $1.21 Billion
Q3 2018 Nov 13, 2018	SELL	$93.92 - $105.72 $3.03 Million - $3.42 Million	-32,304 Reduced 0.23%	14,208,485 $1.38 Billion
Q2 2018 Aug 13, 2018	BUY	$76.01 - $99.03 $36 Million - $47 Million	474,250 Added 3.44%	14,240,789 $1.34 Billion
Q1 2018 May 14, 2018	BUY	$77.67 - $92.63 $273 Million - $326 Million	3,521,244 Added 34.37%	13,766,539 $1.12 Billion
Q4 2017 Feb 13, 2018	BUY	$80.76 - $95.13 $49 Million - $57.7 Million	606,651 Added 6.29%	10,245,295 $914 Million
Q3 2017 Nov 13, 2017	BUY	$80.6 - $94.95 $777 Million - $915 Million	9,638,644	9,638,644 $897 Million

Others Institutions Holding BMRN

# of Institutions

623

Shares Held

181M

Call Options Held

1.73M

Put Options Held

1.73M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Primecap Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Primecap Management CO with notifications on news.

Account

Primecap Management CO Biomarin Pharmaceutical Inc Transaction History